MORF - Morphic Holding, Inc.

Company Profile

Morphic Holding, Inc. operates as a biopharmaceutical company, which engages in the research and development of oral small-molecule integrin therapeutics. The company is headquartered in Waltham, Massachusetts and currently employs 65 full-time employees. The firm is engaged in discovering and developing a pipeline of potentially first-in-class oral small-molecule integrin therapeutics. Integrins are a target class with multiple approved injectable blockbuster drugs for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. The firm is advancing its preclinical pipeline, including its lead wholly-owned program for alpha 4 and beta 7-specific integrin inhibitors affecting inflammation into clinical development for the treatment of inflammatory bowel disease (IBD). The company is also developing MORF-720, a selective oral specific integrin inhibitor into clinical development for the treatment of idiopathic pulmonary fibrosis (IPF).